PhotoPharmics, Inc.


PhotoPharmics is a clinical-stage medical device company dedicated to developing next-generation treatments for neurodegenerative disorders through specialized phototherapy. With over 30 years of research and experience, the company focuses on innovative, non-invasive therapies to improve the lives of patients with conditions like Parkinson’s disease, Alzheimer’s, and other neurodegenerative diseases. Their approach involves specialized light solutions that regulate circadian rhythms and target neural systems, aiming for safe and effective treatments that address both motor and non-motor symptoms. PhotoPharmics is actively conducting clinical trials, including pivotal Phase 3 studies, to validate their therapies and aims to become a standard of care in neurodegenerative disease management.

Industries

biotechnology
health-care
life-science
medical
medical-device
pharmaceutical

Nr. of Employees

small (1-50)

PhotoPharmics, Inc.

3450 North Triumph Boulevard, Lehi, UT 84043 USA


Patents

Ocular treatments for neurological and neuropsychiatric disorders

US-12042471-B2

View Details

Methods for preventing and treating motor related neurological conditions

US-11191478-B2

View Details

Products

Home-use ophthalmic phototherapy device for neurodegenerative disorders

A non-invasive, tabletop ocular phototherapy device designed for daily passive home use to deliver controlled light bandwidths, intensities, and timing aimed at improving motor and non-motor symptoms via retinal stimulation and circadian modulation.


Services

Design and conduct of fully remote, at-home pivotal device trials including participant recruitment, device distribution, virtual visits, remote assessments, and data collection.

Partnerships with academic centers and advisory board experts to develop trial protocols, refine endpoints, and present findings at scientific meetings.

Provision of educational materials, community resources, and support content aimed at patients and caregivers to improve trial awareness, recruitment, and retention.

Expertise Areas

  • Decentralized clinical trial management for medical devices
  • Randomized controlled trial design and execution
  • Phototherapy and circadian-modulation research for neurodegenerative diseases
  • Clinical endpoint selection and biostatistical planning
  • Show More (5)

Key Technologies

  • Ophthalmic phototherapy and controlled light delivery
  • Telemedicine and remote assessment platforms
  • Digital outcome capture tools and online recruitment funnels
  • Clinical motor and quality-of-life outcome instruments (e.g., standardized PD scales)
  • Show More (4)

News & Updates

Funding to support the completion of Phase 3 clinical trial of Celeste® for Parkinson’s disease.

Major milestone in the remote, at-home clinical trial evaluating Celeste® for Parkinson’s.

Appointment of Dr. Robert A. Hauser as Chairman following the passing of Warren Olanow.

An exploration of innovative light therapy approaches for Parkinson’s disease.

Early indicators of Parkinson’s disease before motor symptoms become apparent.

Practical lifestyle and self-care strategies to improve quality of life.

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.